- Home
- CAPR vs NCV Comparison
CAPR vs NCV Comparison
Compare CAPR & NCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- NCV
- Stock Information
- Founded
- CAPR 2005
- NCV 2003
- Country
- CAPR United States
- NCV United States
- Employees
- CAPR N/A
- NCV N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- NCV Finance Companies
- Sector
- CAPR Health Care
- NCV Finance
- Exchange
- CAPR Nasdaq
- NCV Nasdaq
- Market Cap
- CAPR 324.6M
- NCV 326.0M
- IPO Year
- CAPR N/A
- NCV N/A
- Fundamental
- Price
- CAPR $6.28
- NCV $14.75
- Analyst Decision
- CAPR Strong Buy
- NCV
- Analyst Count
- CAPR 8
- NCV 0
- Target Price
- CAPR $24.75
- NCV N/A
- AVG Volume (30 Days)
- CAPR 1.4M
- NCV 405.1K
- Earning Date
- CAPR 08-11-2025
- NCV 01-01-0001
- Dividend Yield
- CAPR N/A
- NCV 12.48%
- EPS Growth
- CAPR N/A
- NCV N/A
- EPS
- CAPR N/A
- NCV N/A
- Revenue
- CAPR $13,392,150.00
- NCV N/A
- Revenue This Year
- CAPR N/A
- NCV N/A
- Revenue Next Year
- CAPR $6,061.53
- NCV N/A
- P/E Ratio
- CAPR N/A
- NCV N/A
- Revenue Growth
- CAPR N/A
- NCV N/A
- 52 Week Low
- CAPR $3.98
- NCV $2.84
- 52 Week High
- CAPR $23.40
- NCV $3.59
- Technical
- Relative Strength Index (RSI)
- CAPR 36.33
- NCV 66.05
- Support Level
- CAPR $6.17
- NCV $14.27
- Resistance Level
- CAPR $7.30
- NCV $14.78
- Average True Range (ATR)
- CAPR 0.43
- NCV 0.14
- MACD
- CAPR -0.11
- NCV 0.01
- Stochastic Oscillator
- CAPR 4.53
- NCV 90.57
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.